Platelet counts at or below 52,000 cells/^l were observed in eight subjects during clinical trials. Seven (one patient was lost to follow-up) were treated with systemic corticosteroids, with resolution. Post-marketing surveillance has reported cases of severe thrombo-cytopenia as well, and physicians should monitor plate let count closely. Patients experiencing thrombocyto-penia while taking efalizumab should discontinue treatment (Raptiva package insert, 2005). Hemolytic anemia, usually 4-6 months after the initiation of therapy, was noted, and treatment with efalizumab should be stopped if this develops.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.